tbuckley/cabot-search huggingface dataset:
Lung metastasis-Harnessed in-Situ adherent porous organic nanosponge-mediated antigen capture for A self-cascaded detained dendritic cells and T cell infiltration
Authors: Ting-Hsien Wu, Yu-Jen Lu, Min-Ren Chiang, Pin-Hua Chen, Yu-Sheng Lee, Ming-Yin Shen, Wen-Hsuan Chiang, Yu-Chen Liu, Chun-Yu Chuang, Hsiao-Chun Amy Lin, Shang-Hsiu Hu
Journal: Biomaterials (2023)
Critical Windows of Maternal Exposure to Biothermal Stress and Birth Weight for Gestational Age in Western Australia
Authors: Sylvester Dodzi Nyadanu, Gizachew A. Tessema, Ben Mullins, Kevin Chai, Maayan Yitshak-Sade, Gavin Pereira
Journal: Environmental Health Perspectives (2023)

There is limited and inconsistent evidence on the risk of ambient temperature on small for gestational age (SGA) and there are no known related studies for large for gestational age (LGA). In addition, previous studies used temperature rather than a biothermal metric.Our aim was to examine the associations and critical susceptible windows of maternal exposure to a biothermal metric [Universal Thermal Climate Index (UTCI)] and the hazards of SGA and LGA.We linked 385,337 singleton term births between 1 January 2000 and 31 December 2015 in Western Australia to daily spatiotemporal UTCI. Distributed lag nonlinear models with Cox regression and multiple models were used to investigate maternal exposure to UTCI from 12 weeks preconception to birth and the adjusted hazard ratios (HRs) of SGA and LGA.Relative to the median exposure, weekly and monthly specific exposures showed potential critical windows of susceptibility for SGA and LGA at extreme exposures, especially during late gestational periods. Monthly exposure showed strong positive associations from the 6th to the 10th gestational months with the highest hazard of 13% for SGA (HR=1.13; 95% CI: 1.10, 1.14) and 7% for LGA (HR=1.07; 95% CI: 1.03, 1.11) at the 10th month for the 1st UTCI centile. Entire pregnancy exposures showed the strongest hazards of 11% for SGA (HR=1.11; 95% CI: 1.04, 1.18) and 3% for LGA (HR=1.03; 95% CI: 0.95, 1.11) at the 99th UTCI centile. By trimesters, the highest hazards were found during the second and first trimesters for SGA and LGA, respectively, at the 99th UTCI centile. Based on estimated interaction effects, male births, mothers who were non-Caucasian, smokers, ≥35 years of age, and rural residents were most vulnerable.Both weekly and monthly specific extreme biothermal stress exposures showed potential critical susceptible windows of SGA and LGA during late gestational periods with disproportionate sociodemographic vulnerabilities. https://doi.org/10.1289/EHP12660.
Extraperitonealization of the ileal conduit decreases the risk of parastomal hernia: A single-center, randomized clinical trial
Authors: Zhaohui Zhou, Longbin Xiong, Kai Yao, Huali Ma, Wensu Wei, Zhiling Zhang, Shengjie Guo, Pei Dong, Xiangdong Li, Lijuan Jiang, Dong Chen, Zike Qin, Hui Han, Yunlin Ye, Yonghong Li, Yanjun Wang, Zhiming Wu, Li Tian, Chunping Yu, Fangjian Zhou, Zhiyong Li, Zhuowei Liu
Journal: Cell Reports Medicine (2023)

Parastomal hernia (PSH) is a common complication in patients receiving ileal conduit urinary diversion after radical cystectomy. In this randomized controlled clinical trial, we validate our previous finding that extraperitonealization of ileal conduit decreases incidence of PSH. In total, 104 consecutive patients undergoing radical cystectomy at Sun Yat-sen University Cancer Center are randomized 1:1 to receive either modified (extraperitonealized) ileal conduit (n = 52) or conventional ileal conduit (n = 52). Primary endpoint is incidence of radiological PSH during follow-up. Incidence of radiological PSH is lower in the modified group than in the conventional group (11.5% vs. 28.8%; p = 0.028) after a median follow-up of 32 months, corresponding to a hazard ratio of 0.374 (95% confidence interval: 0.145–0.965, p = 0.034) in the modified conduit group. The results support our previous finding that extraperitonealization of the ileal conduit is effective for reducing risk of PSH in patients receiving ileal conduit diversion.
Climate Change, Summer Temperature, and Heat-Related Mortality in Finland: Multicohort Study with Projections for a Sustainable vs. Fossil-Fueled Future to 2050
Authors: Mika Kivimäki, G. David Batty, Jaana Pentti, Juuso Suomi, Solja T. Nyberg, Joonas Merikanto, Kalle Nordling, Jenni Ervasti, Sakari B. Suominen, Antti-Ilari Partanen, Sari Stenholm, Jukka Käyhkö, Jussi Vahtera
Journal: Environmental Health Perspectives (2023)

Climate change scenarios illustrate various pathways in terms of global warming ranging from "sustainable development" (Shared Socioeconomic Pathway SSP1-1.9), the best-case scenario, to 'fossil-fueled development' (SSP5-8.5), the worst-case scenario.
Molecular and Metabolic Analysis of Arsenic-Exposed Humanized AS3MT Mice
Authors: Jenna Todero, Christelle Douillet, Alexandria J. Shumway, Beverly H. Koller, Matt Kanke, Daryl J. Phuong, Miroslav Stýblo, Praveen Sethupathy
Journal: Environmental Health Perspectives (2023)

Chronic exposure to inorganic arsenic (iAs) has been associated with type 2 diabetes (T2D). However, potential sex divergence and the underlying mechanisms remain understudied. iAs is not metabolized uniformly across species, which is a limitation of typical exposure studies in rodent models. The development of a new "humanized" mouse model overcomes this limitation. In this study, we leveraged this model to study sex differences in the context of iAs exposure.
Measuring moral distress and moral injury: A systematic review and content analysis of existing scales
Authors: Stephanie A Houle, Natalie Ein, Julia Gervasio, Rachel A Plouffe, Brett T Litz, R Nicholas Carleton, Kevin T Hansen, Jenny J W Liu, Andrea R Ashbaugh, Walter Callaghan, Megan M Thompson, Bethany Easterbrook, Lorraine Smith-MacDonald, Sara Rodrigues, Stéphanie A H Bélanger, Katherine Bright, Ruth A Lanius, Clara Baker, William Younger, Suzette Bremault-Phillips, Fardous Hosseiny, J Don Richardson, Anthony Nazarov
Journal: Clinical Psychology Review (2023)

Moral distress (MD) and moral injury (MI) are related constructs describing the negative consequences of morally challenging stressors. Despite growing support for the clinical relevance of these constructs, ongoing challenges regarding measurement quality risk limiting research and clinical advances. This study summarizes the nature, quality, and utility of existing MD and MI scales, and provides recommendations for future use.
Collectin 11 has a pivotal role in host defense against kidney and bladder infection in mice
Authors: Kun-Yi Wu, Bo Cao, Wan-Bing Chen, Weiju Wu, Shujuan Zhao, Xiao-Yun Min, Jurong Yang, Jin Han, Xia Dong, Na Wang, Yi Wu, Peter Garred, Steven H Sacks, Wuding Zhou, Ke Li
Journal: Kidney International (2023)
Ubiquitination of cytoplasmic HMGB1 by RNF186 regulates hepatic lipophagy in non-alcoholic fatty liver disease
Authors: Jiang Du, Xiang Ji, Bo Xu, Qizhang Du, Yujie Li, Bing Zhou, Xinlei Liu, Zhihao Xu, Yan Jiang, Beilin Kou, Zexin Li, Chaochu Cui, Juntang Lin
Journal: Metabolism (2023)
Associations between Phthalate Metabolite Concentrations in Follicular Fluid and Reproductive Outcomes among Women Undergoing <i>in Vitro</i> Fertilization/Intracytoplasmic Sperm Injection Treatment
Authors: Wen Yao, Chong Liu, Dan-Yu Qin, Xiao-Qiong Yuan, Qing-Yun Yao, Ni-Jie Li, Yong Huang, Wen-Tao Rao, Yu-Ying Li, Yan-Ling Deng, Qiang Zeng, Yu-Feng Li
Journal: Environmental Health Perspectives (2023)

Phthalates have been reported to impair fertility in various studies. However, evidence exploring the associations between phthalate metabolites in follicular fluid (FF) and reproductive outcomes is lacking.
Crocus genome reveals the evolutionary origin of crocin biosynthesis
Authors: Zhichao Xu, Shanshan Chen, Yalin Wang, Ya Tian, Xiaotong Wang, Tianyi Xin, Zishan Li, Xin Hua, Shengnan Tan, Wei Sun, Xiangdong Pu, Hui Yao, Ranran Gao, Jingyuan Song
Journal: Acta Pharmaceutica Sinica B (2023)

(saffron) is a globally autumn-flowering plant, and its stigmas are the most expensive spice and valuable herb medicine.
A systematic review and research agenda of internalized sexual stigma in sexual minority individuals: Evidence from longitudinal and intervention studies
Authors: Josh Nguyen, Joel Anderson, Christopher A. Pepping
Journal: Clinical Psychology Review (2023)

Internalized sexual stigma is a well-established risk factor for poor mental health among sexual minority individuals. However, there has been no synthesis of the literature pertaining to risk and protective factors that influence the development of internalized sexual stigma over time. This systematic review presents findings from 31 studies addressing this question (n = 9192); 23 studies examined psychosocial and sociodemographic predictors of internalized sexual stigma among sexual minority individuals, and eight studies tested the effects of psychological interventions on internalized sexual stigma. Longitudinal studies highlight the stability of internalized sexual stigma over time, and the role of stigma and discrimination, proximal minority stressors (e.g., outness, concealment), and psychological factors (e.g., depressive and anxious symptoms, coping styles, and demoralization) in predicting subsequent internalized sexual stigma. Demographic factors appear to play only a limited role in predicting subsequent internalized sexual stigma. Finally, most intervention studies found no significant effects in reducing internalized sexual stigma, with three exceptions finding significant intervention effects among young sexual minority individuals. We conclude by outlining a theory-driven model of internalized stigma and a research agenda to test more nuanced models of internalized stigma that include multifactorial risk indices.
HIV and mpox: Evaluation of clinical course and outcomes from an international dermatologic registry
Authors: Alexis G. Strahan, Cristina Galvan Casas, Sonya Prasad, Lucinda Claire Fuller, Klint Peebles, Andrea Carugno, Kieron S. Leslie, Joanna L. Harp, Teodora Pumnea, Devon E. McMahon, Misha Rosenbach, Janet E. Lubov, Geoffrey Chen, Ann M. Pacheco, Lindy P. Fox, Allen McMillen, Henry W. Lim, Alexander J. Stratigos, Terrence A. Cronin, Mark D. Kaufmann, George J. Hruza, Lars E. French, Esther E. Freeman
Journal: Journal of the American Academy of Dermatology (2023)
Atherosclerotic three-layer nanomatrix vascular sheets for high-throughput therapeutic evaluation
Authors: Jun Chen, Xixi Zhang, Robbie Cross, Yujin Ahn, Gillian Huskin, Will Evans, Patrick Taejoon Hwang, Jeong-A Kim, Brigitta C Brott, Hanjoong Jo, Young-Sup Yoon, Ho-Wook Jun
Journal: Biomaterials (2023)

In vitro atherosclerosis models are essential to evaluate therapeutics before in vivo and clinical studies, but significant limitations remain, such as the lack of three-layer vascular architecture and limited atherosclerotic features. Moreover, no scalable 3D atherosclerosis model is available for making high-throughput assays for therapeutic evaluation. Herein, we report an in vitro 3D three-layer nanomatrix vascular sheet with critical atherosclerosis multi-features (VSA), including endothelial dysfunction, monocyte recruitment, macrophages, extracellular matrix remodeling, smooth muscle cell phenotype transition, inflammatory cytokine secretion, foam cells, and calcification initiation. Notably, we present the creation of high-throughput functional assays with VSAs and the use of these assays for evaluating therapeutics for atherosclerosis treatment. The therapeutics include conventional drugs (statin and sirolimus), candidates for treating atherosclerosis (curcumin and colchicine), and potential gene therapy (miR-146a-loaded liposomes). The high efficiency and flexibility of the scalable VSA functional assays should facilitate drug discovery and development for atherosclerosis.
A parathyroid hormone related supramolecular peptide for multi-functionalized osteoregeneration
Authors: Zhuowen Hao, Qinyu Feng, Yi Wang, Ying Wang, Hanke Li, Yingkun Hu, Tianhong Chen, Junwu Wang, Renxin Chen, Xuan Lv, Zhiqiang Yang, Jiayao Chen, Xiaodong Guo, Jingfeng Li
Journal: Bioactive Materials (2023)

Supramolecular peptide nanofiber hydrogels are emerging biomaterials for tissue engineering, but it is difficult to fabricate multi-functional systems by simply mixing several short-motif-modified supramolecular peptides because relatively abundant motifs generally hinder nanofiber cross-linking or the formation of long nanofiber. Coupling bioactive factors to the assembling backbone is an ideal strategy to design multi-functional supramolecular peptides in spite of challenging synthesis and purification. Herein, a multi-functional supramolecular peptide, P1R16, is developed by coupling a bioactive factor, parathyroid hormone related peptide 1 (PTHrP-1), to the basic supramolecular peptide RADA16-Ⅰ via solid-phase synthesis. It is found that P1R16 self-assembles into long nanofibers and co-assembles with RADA16-Ⅰ to form nanofiber hydrogels, thus coupling PTHrP-1 to hydrogel matrix. P1R16 nanofiber retains osteoinductive activity in a dose-dependent manner, and P1R16/RADA16-Ⅰ nanofiber hydrogels promote osteogenesis, angiogenesis and osteoclastogenesis in vitro and induce multi-functionalized osteoregeneration by intramembranous ossification and bone remodeling in vivo when loaded to collagen (Col) scaffolds. Abundant red blood marrow formation, ideal osteointegration and adapted degradation are observed in the 50% P1R16/Col scaffold group. Therefore, this study provides a promising strategy to develop multi-functional supramolecular peptides and a new method to topically administrate parathyroid hormone or parathyroid hormone related peptides for non-healing bone defects.
Longitudinal Assessment of Pancreas Volume by MRI Predicts Progression to Stage 3 Type 1 Diabetes
Authors: John Virostko, Jordan J. Wright, Jonathan M. Williams, Melissa A. Hilmes, Taylor M. Triolo, Hali Broncucia, Liping Du, Hakmook Kang, Shreya Nallaparaju, Leah Galvez Valencia, Demetra Reyes, Brenna Hammel, William E. Russell, Louis H. Philipson, Michaela Waibel, Thomas W.H. Kay, Helen E. Thomas, Siri Atma W. Greeley, Andrea K. Steck, Alvin C. Powers, Daniel J. Moore
Journal: Diabetes Care (2023)

This multicenter prospective cohort study compared pancreas volume as assessed by MRI, metabolic scores derived from oral glucose tolerance testing (OGTT), and a combination of pancreas volume and metabolic scores for predicting progression to stage 3 type 1 diabetes (T1D) in individuals with multiple diabetes-related autoantibodies.
Outcomes With Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Baseline Insulin Resistance
Authors: Thomas Ebert, Stefan D. Anker, Luis M. Ruilope, Paola Fioretto, Vivian Fonseca, Guillermo E. Umpierrez, Andreas L. Birkenfeld, Robert Lawatscheck, Charlie Scott, Katja Rohwedder, Peter Rossing
Journal: Diabetes Care (2023)

OBJECTIVE To explore whether insulin resistance, assessed by estimated glucose disposal rate (eGDR), is associated with cardiorenal risk and whether it modifies finerenone efficacy. RESEARCH DESIGN AND METHODS In FIDELITY (N = 13,026), patients with type 2 diabetes, either 1) urine albumin-to-creatinine ratio (UACR) of ≥30 to &amp;lt;300 mg/g and estimated glomerular filtration rate (eGFR) of ≥25 to ≤90 mL/min/1.73 m2 or 2) UACR of ≥300 to ≤5,000 mg/g and eGFR of ≥25 mL/min/1.73 m2, who also received optimized renin-angiotensin system blockade, were randomized to finerenone or placebo. Outcomes included cardiovascular (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure) and kidney (kidney failure, sustained decrease of ≥57% in eGFR from baseline, or renal death) composites. eGDR was calculated using waist circumference, hypertension status, and glycated hemoglobin for 12,964 patients. RESULTS Median eGDR was 4.1 mg/kg/min. eGDR &amp;lt;median (insulin resistant) was associated with higher cardiovascular event incidence regardless of treatment versus ≥median (insulin sensitive) (incidence rate/100 patient-years of 5.18 and 6.34 [for finerenone and placebo] vs. 3.47 and 3.76 [for finerenone and placebo], respectively). However, eGDR was not associated with kidney outcomes. There was no significant heterogeneity for effects of finerenone by eGDR on cardiovascular (&amp;lt;median: hazard ratio [HR] 0.81, 95% CI 0.72–0.92; ≥median: HR = 0.92, 95% CI 0.79–1.06; P interaction = 0.23) or kidney outcomes (&amp;lt;median: HR = 0.84, 95% CI 0.68–1.02; ≥median: HR = 0.70, 95% CI 0.58–0.85; P interaction = 0.28). Overall, finerenone demonstrated similar safety between subgroups. Sensitivity analyses were consistent. CONCLUSIONS Insulin resistance was associated with increased cardiovascular (but not kidney) risk and did not modify finerenone efficacy.
Construct validity evidence reporting practices for the Reading the Mind in the Eyes Test: A systematic scoping review
Authors: Wendy C Higgins, David M Kaplan, Eliane Deschrijver, Robert M Ross
Journal: Clinical Psychology Review (2023)

The Reading the Mind in the Eyes Test (RMET) is one of the most influential measures of social cognitive ability, and it has been used extensively in clinical populations. However, questions have been raised about the validity of RMET scores. We conducted a systematic scoping review of the validity evidence reported in studies that administered the RMET (n = 1461; of which 804 included at least one clinical sample) with a focus on six key dimensions: internal consistency, test-retest reliability, factor structure, convergent validity, discriminant validity, and known group validity. Strikingly, 63% of these studies failed to provide validity evidence from any of these six categories. Moreover, when evidence was reported, it frequently failed to meet widely accepted validity standards. Overall, our results suggest a troubling conclusion: the validity of RMET scores (and the research findings based on them) are largely unsubstantiated and uninterpretable. More broadly, this project demonstrates how unaddressed measurement issues can undermine a voluminous psychological literature.
Gut microbiome responds to alteration in female sex hormone status and exacerbates metabolic dysfunction
Authors: Tzu-Wen L. Cross, Abigayle M. R. Simpson, Ching-Yen Lin, Natasha M. Hottmann, Aadra P. Bhatt, Samuel J. Pellock, Erik R. Nelson, Brett R. Loman, Matthew A. Wallig, Eugenio I. Vivas, Jan Suchodolski, Matthew R. Redinbo, Federico E. Rey, Kelly S. Swanson
Journal: Gut Microbes (2023)

Women are at significantly greater risk of metabolic dysfunction after menopause, which subsequently leads to numerous chronic illnesses. The gut microbiome is associated with obesity and metabolic dysfunction, but its interaction with female sex hormone status and the resulting impact on host metabolism remains unclear. Herein, we characterized inflammatory and metabolic phenotypes as well as the gut microbiome associated with ovariectomy and high-fat diet feeding, compared to gonadal intact and low-fat diet controls. We then performed fecal microbiota transplantation (FMT) using gnotobiotic mice to identify the impact of ovariectomy-associated gut microbiome on inflammatory and metabolic outcomes. We demonstrated that ovariectomy led to greater gastrointestinal permeability and inflammation of the gut and metabolic organs, and that a high-fat diet exacerbated these phenotypes. Ovariectomy also led to alteration of the gut microbiome, including greater fecal β-glucuronidase activity. However, differential changes in the gut microbiome only occurred when fed a low-fat diet, not the high-fat diet. Gnotobiotic mice that received the gut microbiome from ovariectomized mice fed the low-fat diet had greater weight gain and hepatic gene expression related to metabolic dysfunction and inflammation than those that received intact sham control-associated microbiome. These results indicate that the gut microbiome responds to alterations in female sex hormone status and contributes to metabolic dysfunction. Identifying and developing gut microbiome-targeted modulators to regulate sex hormones may be useful therapeutically in remediating menopause-related diseases.
Mode of Detection of Second Breast Cancers in Patients Undergoing Surveillance After Treatment of Ductal Carcinoma in Situ
Authors: Bethany T. Waites, Liisa Lyon, Gillian Kuehner, Patience Odele, Laurel A. Habel, Raymond Liu
Journal: Journal of the National Comprehensive Cancer Network (2023)

Background: For patients undergoing posttreatment surveillance after ductal carcinoma in situ (DCIS), the NCCN Guidelines for Breast Cancer recommend annual breast imaging and physical examination every 6 to 12 months for 5 years, and then annually. The aim of our study was to evaluate the modes of detection (imaging, patient reported, or physical examination) of second cancers in a cohort of patients undergoing surveillance after primary DCIS treatment to better inform surveillance recommendations. Methods: We performed a retrospective cohort study of patients with DCIS treated between January 1, 2008, and December 31, 2011, within a large integrated health care system. Information on patient demographics, index DCIS treatment, tumor characteristics, and mode of detection of second breast cancer was obtained from the electronic health record or chart review. Results: Our study cohort consisted of 1,550 women, with a median age of 59 years at diagnosis. Surgical treatment of DCIS included lumpectomy (75.0%; n=1,162), unilateral mastectomy (21.1%; n=327), or bilateral mastectomy (3.9%; n=61), with or without sentinel lymph node biopsy. Additionally, 44.4% (n=688) and 28.3% (n=438) received radiation and endocrine therapies, respectively. Median follow-up was 10 years, during which 179 (11.5%) women were diagnosed with a second breast cancer. Of the second cancers, 43.0% (n=77) were ipsilateral and 54.8% (n=98) contralateral, and 2.2% (n=4) presented with distant metastases; 61.5% (n=110) were invasive, 36.3% (n=65) were DCIS, and 2.2% (n=4) were Paget’s disease. Second breast cancers were imaging-detected in 74.3% (n=133) of cases, patient-detected in 20.1% (n=36), physician-detected in 2.2% (n=4), and detected incidentally on imaging or pathology from procedures unrelated to oncologic care in 3.4% (n=6). Conclusions: In our cohort of patients undergoing surveillance following diagnosis and treatment of DCIS, 2% of second breast cancers were detected by a clinical breast examination. This suggests that survivorship care should prioritize mammography and patient education regarding breast self-examination and symptoms that warrant evaluation to detect second breast cancers.